Alpha-hemoglobin-stabilizing protein (AHSP): a modulatory factor in β-thalassemia
- PMID: 31894534
- DOI: 10.1007/s12185-019-02806-8
Alpha-hemoglobin-stabilizing protein (AHSP): a modulatory factor in β-thalassemia
Abstract
Hemoglobin (Hb) is an iron-containing metalloprotein that transports oxygen molecules from the lungs to the rest of the human body. Among the different variants of Hb, HbA1 is the most common and is composed of two alpha (αHb) and two beta globin chains (βHb) constructing a heterotetrameric protein complex (α2β2). Due to the higher number of AHSP genes, there is a tendency to produce approximately twice as much of α subunit as β subunit. Therefore, there is a chance of presenting excess α subunit leftover in human blood plasma; excess subunits subsequently bind with each other and aggregates β-thalassemia occurs due to lack of or reduced numbers of βHb subunit. Alpha-hemoglobin-stabilizing protein (AHSP) is a scavenger protein which acts as a molecular chaperon by reversibly binding with free αHb forming a complex (AHSP-αHb) that prevents aggregation and precipitation preventing deleterious effects towards developing serious human diseases including β-thalassemia. Clinical severity worsens if mutations in AHSP gene co-occur in patients with β-thalassemia. Considering the mechanism of action of AHSP and its contribution to ameliorating β-thalassemia severity, it could potentially be used as a modulatory agent in the treatment of β-thalassemia.
Keywords: AHSP; Chaperone; Hemoglobin; β-Thalassemia.
Similar articles
-
Role of alpha-hemoglobin-stabilizing protein in normal erythropoiesis and beta-thalassemia.Ann N Y Acad Sci. 2005;1054:103-17. doi: 10.1196/annals.1345.013. Ann N Y Acad Sci. 2005. PMID: 16339656 Review.
-
Transgenic human alpha-hemoglobin stabilizing protein could partially relieve betaIVS-2-654-thalassemia syndrome in model mice.Hum Gene Ther. 2010 Feb;21(2):149-56. doi: 10.1089/hum.2009.132. Hum Gene Ther. 2010. PMID: 20063986
-
Relationship between AHSP gene expression, β/α globin mRNA ratio, and clinical severity of the β-thalassemia patients.Ann Clin Lab Sci. 2014 Spring;44(2):189-93. Ann Clin Lab Sci. 2014. PMID: 24795058
-
Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with beta thalassemia.Blood. 2004 May 1;103(9):3296-9. doi: 10.1182/blood-2003-11-3957. Epub 2004 Jan 8. Blood. 2004. PMID: 14715623
-
AHSP and beta-thalassemia: a possible genetic modifier.Hematology. 2005 Apr;10(2):157-61. doi: 10.1080/10245330500067280. Hematology. 2005. PMID: 16019463 Review.
Cited by
-
Trans-acting genetic modifiers of clinical severity in heterozygous β-Thalassemia trait.Ann Hematol. 2024 Nov;103(11):4437-4447. doi: 10.1007/s00277-024-06007-0. Epub 2024 Sep 24. Ann Hematol. 2024. PMID: 39316111 Review.
-
Identification of iron metabolism-related genes as diagnostic signatures in sepsis by blood transcriptomic analysis.Open Life Sci. 2023 Feb 9;18(1):20220549. doi: 10.1515/biol-2022-0549. eCollection 2023. Open Life Sci. 2023. PMID: 36820206 Free PMC article.
-
Increased Expression of α-Hemoglobin Stabilizing Protein (AHSP) mRNA in Erythroid Precursor Cells Isolated from β-Thalassemia Patients Treated with Sirolimus (Rapamycin).J Clin Med. 2024 Apr 24;13(9):2479. doi: 10.3390/jcm13092479. J Clin Med. 2024. PMID: 38731008 Free PMC article.
-
The interactions between ineffective erythropoiesis and ferroptosis in β-thalassemia.Front Physiol. 2024 Feb 26;15:1346173. doi: 10.3389/fphys.2024.1346173. eCollection 2024. Front Physiol. 2024. PMID: 38468700 Free PMC article. Review.
-
Iron-Loading Anemias.Adv Exp Med Biol. 2025;1480:145-161. doi: 10.1007/978-3-031-92033-2_11. Adv Exp Med Biol. 2025. PMID: 40603790 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous